Eric A. Finkelstein, PhD, MHA; and Derek S. Brown, PhD

This editorial discusses the cost implication of bariatric surgery and whether or not return on investment analysis should be used to make coverage decisions.

Kathleen M. Fox, MHS, PhD; John M. Brooks, PhD; and Jennifer Kim, PharmD

The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.

Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP

Diabetes mellitus (DM) prediction equations developed by the Framingham Offspring Study were validated, but the point score underestimated DM risk in an HMO population.

Joel Lexchin, MD; and Barbara Mintzes, PhD

Pharmacoeconomic analyses appear to account for differences in recommendations made regarding public payment when national bodies consider the same drugs for the same indication.

Pierre-Yves Cremieux, PhD; Henry Buchwald, MD, PhD; Scott A. Shikora, MD; Arindam Ghosh, PhD; Haixia Elaine Yang, PhD; and Marric Buessing, BA

Mark P. Connolly, MHE; Michael S. Pollard, PhD; Stijn Hoorens, MSc; Brian R. Kaplan, MD; Selwyn P. Oskowitz, MD; and Sherman J. Silber, MD

We estimate the future net tax contributions from an IVF-conceived child to highlight that removing barriers to fertility treatments can have long-term economic benefits.

Anna N. A. Tosteson, ScD; Russel T. Burge, PhD; Deborah A. Marshall, PhD; and Robert Lindsay, MD

Osteoporosis treatment for high-risk women is cost-effective, with bisphosphonates providing the most benefit at the lowest cost.

Kathleen A. Fairman, MA. Author reply by Michael E. Chernew, PhD, and Joseph P. Newhouse, PhD

Christopher N. Mills, MD, MPH. Author reply by William E. Lafferty, MD, and M. Robyn Andersen, PhD, MPH